LymphedemaV1, Pmc, Checkpoint, bibRecord, 002B41

Breast Cancer: State of the Art and New Findings

Identifieur interne : 002B41 ( Pmc/Checkpoint ); précédent : 002B40; suivant : 002B42

Breast Cancer: State of the Art and New Findings

Auteurs : C. Melcher ; C. Scholz ; B. J Ger ; C. Hagenbeck ; B. Rack ; W. Janni

Source :

Geburtshilfe und Frauenheilkunde [ 0016-5751 ] ; 2012.

RBID : PMC:4651153

Abstract

Advances in research have a highly influential role to play in the strategy of early detection, treatment and aftercare of breast cancer and therefore everyday clinical practice. Newly-defined prognosis factors and a new form of molecular subtype classification, for example, are intended to help identify patients who will actually benefit from chemotherapy. In the field of neoadjuvant chemotherapy, the inclusion of the angiogenesis inhibitor Bevacizumab and dual antiHER2 therapy is being discussed. Whatʼs more, where defined criteria are met, even with positive sentinel lymph nodes, axillary dissection is not performed; besides bisphosphonates RANKL antibody Denosumab is now an option in the treatment of bone metastases.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651153

DOI: 10.1055/s-0031-1298320
PubMed: 26640286
PubMed Central: 4651153

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: 000057
to stream Pmc, to step Curation: 000057

Links to Exploration step

PMC:4651153

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Breast Cancer: State of the Art and New Findings</title>
<author><name sortKey="Melcher, C" sort="Melcher, C" uniqKey="Melcher C" first="C." last="Melcher">C. Melcher</name>
<affiliation><nlm:aff id="AF446-1"><institution>Womenʼs Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf</institution>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Scholz, C" sort="Scholz, C" uniqKey="Scholz C" first="C." last="Scholz">C. Scholz</name>
<affiliation><nlm:aff id="AF446-1"><institution>Womenʼs Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf</institution>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="J Ger, B" sort="J Ger, B" uniqKey="J Ger B" first="B." last="J Ger">B. J Ger</name>
<affiliation><nlm:aff id="AF446-2"><institution>Department and Outpatient Clinic for Gynaecology and Obstetrics – Innenstadt, Hospital of the Ludwig Maximilian , University of Munich, Munich</institution>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hagenbeck, C" sort="Hagenbeck, C" uniqKey="Hagenbeck C" first="C." last="Hagenbeck">C. Hagenbeck</name>
<affiliation><nlm:aff id="AF446-1"><institution>Womenʼs Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf</institution>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Rack, B" sort="Rack, B" uniqKey="Rack B" first="B." last="Rack">B. Rack</name>
<affiliation><nlm:aff id="AF446-2"><institution>Department and Outpatient Clinic for Gynaecology and Obstetrics – Innenstadt, Hospital of the Ludwig Maximilian , University of Munich, Munich</institution>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Janni, W" sort="Janni, W" uniqKey="Janni W" first="W." last="Janni">W. Janni</name>
<affiliation><nlm:aff id="AF446-1"><institution>Womenʼs Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf</institution>
</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">26640286</idno>
<idno type="pmc">4651153</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651153</idno>
<idno type="RBID">PMC:4651153</idno>
<idno type="doi">10.1055/s-0031-1298320</idno>
<date when="2012">2012</date>
<idno type="wicri:Area/Pmc/Corpus">000057</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000057</idno>
<idno type="wicri:Area/Pmc/Curation">000057</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000057</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002B41</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002B41</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Breast Cancer: State of the Art and New Findings</title>
<author><name sortKey="Melcher, C" sort="Melcher, C" uniqKey="Melcher C" first="C." last="Melcher">C. Melcher</name>
<affiliation><nlm:aff id="AF446-1"><institution>Womenʼs Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf</institution>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Scholz, C" sort="Scholz, C" uniqKey="Scholz C" first="C." last="Scholz">C. Scholz</name>
<affiliation><nlm:aff id="AF446-1"><institution>Womenʼs Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf</institution>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="J Ger, B" sort="J Ger, B" uniqKey="J Ger B" first="B." last="J Ger">B. J Ger</name>
<affiliation><nlm:aff id="AF446-2"><institution>Department and Outpatient Clinic for Gynaecology and Obstetrics – Innenstadt, Hospital of the Ludwig Maximilian , University of Munich, Munich</institution>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Hagenbeck, C" sort="Hagenbeck, C" uniqKey="Hagenbeck C" first="C." last="Hagenbeck">C. Hagenbeck</name>
<affiliation><nlm:aff id="AF446-1"><institution>Womenʼs Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf</institution>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Rack, B" sort="Rack, B" uniqKey="Rack B" first="B." last="Rack">B. Rack</name>
<affiliation><nlm:aff id="AF446-2"><institution>Department and Outpatient Clinic for Gynaecology and Obstetrics – Innenstadt, Hospital of the Ludwig Maximilian , University of Munich, Munich</institution>
</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Janni, W" sort="Janni, W" uniqKey="Janni W" first="W." last="Janni">W. Janni</name>
<affiliation><nlm:aff id="AF446-1"><institution>Womenʼs Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf</institution>
</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Geburtshilfe und Frauenheilkunde</title>
<idno type="ISSN">0016-5751</idno>
<idno type="eISSN">1438-8804</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Advances in research have a highly influential role to play in the strategy of early detection, treatment and aftercare of breast cancer and therefore everyday clinical practice. Newly-defined prognosis factors and a new form of molecular subtype classification, for example, are intended to help identify patients who will actually benefit from chemotherapy. In the field of neoadjuvant chemotherapy, the inclusion of the angiogenesis inhibitor Bevacizumab and dual antiHER2 therapy is being discussed. Whatʼs more, where defined criteria are met, even with positive sentinel lymph nodes, axillary dissection is not performed; besides bisphosphonates RANKL antibody Denosumab is now an option in the treatment of bone metastases.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Geburtshilfe Frauenheilkd</journal-id>
<journal-id journal-id-type="iso-abbrev">Geburtshilfe Frauenheilkd</journal-id>
<journal-id journal-id-type="publisher-id">Geburtshilfe und Frauenheilkunde</journal-id>
<journal-title-group><journal-title>Geburtshilfe und Frauenheilkunde</journal-title>
</journal-title-group>
<issn pub-type="ppub">0016-5751</issn>
<issn pub-type="epub">1438-8804</issn>
<publisher><publisher-name>Georg Thieme Verlag KG</publisher-name>
<publisher-loc>Stuttgart · New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">26640286</article-id>
<article-id pub-id-type="pmc">4651153</article-id>
<article-id pub-id-type="doi">10.1055/s-0031-1298320</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Breast Cancer: State of the Art and New Findings</article-title>
<trans-title-group xml:lang="de"><trans-title>Das Mammakarzinom: State of the Art und Neuigkeiten</trans-title>
</trans-title-group>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Melcher</surname>
<given-names>C.</given-names>
</name>
<xref rid="AF446-1" ref-type="aff">1</xref>
<xref rid="CO-1" ref-type="author-notes"></xref>
</contrib>
<contrib contrib-type="author"><name><surname>Scholz</surname>
<given-names>C.</given-names>
</name>
<xref rid="AF446-1" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Jäger</surname>
<given-names>B.</given-names>
</name>
<xref rid="AF446-2" ref-type="aff">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Hagenbeck</surname>
<given-names>C.</given-names>
</name>
<xref rid="AF446-1" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Rack</surname>
<given-names>B.</given-names>
</name>
<xref rid="AF446-2" ref-type="aff">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Janni</surname>
<given-names>W.</given-names>
</name>
<xref rid="AF446-1" ref-type="aff">1</xref>
</contrib>
</contrib-group>
<aff id="AF446-1"><label>1</label>
<institution>Womenʼs Clinic, Hospital of the Heinrich Heine University of Düsseldorf, Düsseldorf</institution>
</aff>
<aff id="AF446-2"><label>2</label>
<institution>Department and Outpatient Clinic for Gynaecology and Obstetrics – Innenstadt, Hospital of the Ludwig Maximilian , University of Munich, Munich</institution>
</aff>
<author-notes><corresp id="CO-1"><bold>Correspondence </bold>
Dr. Carola Melcher <institution>Womenʼs Clinic, Hospital of the Heinrich Heine University of Düsseldorf</institution>
<addr-line>Moorenstraße 5</addr-line>
<addr-line>40225 Düsseldorf</addr-line>
<email>carola.melcher@med.uni-duesseldorf.de</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub"><month>3</month>
<year>2012</year>
</pub-date>
<volume>72</volume>
<issue>3</issue>
<fpage>215</fpage>
<lpage>224</lpage>
<history><date date-type="received"><day>22</day>
<month>12</month>
<year>2011</year>
</date>
<date date-type="rev-recd"><day>12</day>
<month>3</month>
<year>2012</year>
</date>
<date date-type="accepted"><day>02</day>
<month>3</month>
<year>2012</year>
</date>
</history>
<permissions><copyright-statement>© Thieme Medical Publishers</copyright-statement>
</permissions>
<abstract><p>Advances in research have a highly influential role to play in the strategy of early detection, treatment and aftercare of breast cancer and therefore everyday clinical practice. Newly-defined prognosis factors and a new form of molecular subtype classification, for example, are intended to help identify patients who will actually benefit from chemotherapy. In the field of neoadjuvant chemotherapy, the inclusion of the angiogenesis inhibitor Bevacizumab and dual antiHER2 therapy is being discussed. Whatʼs more, where defined criteria are met, even with positive sentinel lymph nodes, axillary dissection is not performed; besides bisphosphonates RANKL antibody Denosumab is now an option in the treatment of bone metastases.</p>
</abstract>
<trans-abstract xml:lang="de"><sec><title>Zusammenfassung</title>
<p>Die Fortschritte in der Forschung beeinflussen maßgeblich die Strategie der Früherkennung, Behandlung und Nachsorge des Mammakarzinoms und damit den klinischen Alltag. Neu definierte Prognosefaktoren sowie eine neue molekulare Subtypen-Klassifikation sollen helfen, Patientinnen zu identifizieren, die tatsächlich von einer Chemotherapie profitieren werden. Im Bereich der neoadjuvanten Chemotherapie werden die Hinzunahme des Angiogenesehemmers Bevacizumab und eine duale Anti-HER2-Therapie diskutiert. Zudem darf beim Vorliegen definierter Kriterien auch bei positivem Sentinellymphknoten auf eine Axilladissektion verzichtet werden, und bei der Behandlung ossärer Metastasen steht uns nun neben den Bisphosphonaten der RANKL-Antikörper Denosumab zur Verfügung.</p>
</sec>
</trans-abstract>
<kwd-group xml:lang="en"><title>Key words</title>
<kwd>breast cancer</kwd>
<kwd>molecular genetic subtypes</kwd>
<kwd>chemotherapy</kwd>
<kwd>targeted therapy</kwd>
<kwd>endocrine therapy</kwd>
<kwd>radiotherapy</kwd>
<kwd>prognosis</kwd>
</kwd-group>
<kwd-group xml:lang="de"><title>Schlüsselwörter</title>
<kwd>Mammakarzinom</kwd>
<kwd>molekulargenetische Subtypen</kwd>
<kwd>Chemotherapie</kwd>
<kwd>zielgerichtete Therapie</kwd>
<kwd>endokrine Therapie</kwd>
<kwd>Radiotherapie</kwd>
<kwd>Prognose</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
<affiliations><list></list>
<tree><noCountry><name sortKey="Hagenbeck, C" sort="Hagenbeck, C" uniqKey="Hagenbeck C" first="C." last="Hagenbeck">C. Hagenbeck</name>
<name sortKey="J Ger, B" sort="J Ger, B" uniqKey="J Ger B" first="B." last="J Ger">B. J Ger</name>
<name sortKey="Janni, W" sort="Janni, W" uniqKey="Janni W" first="W." last="Janni">W. Janni</name>
<name sortKey="Melcher, C" sort="Melcher, C" uniqKey="Melcher C" first="C." last="Melcher">C. Melcher</name>
<name sortKey="Rack, B" sort="Rack, B" uniqKey="Rack B" first="B." last="Rack">B. Rack</name>
<name sortKey="Scholz, C" sort="Scholz, C" uniqKey="Scholz C" first="C." last="Scholz">C. Scholz</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B41 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 002B41 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Pmc
   |étape=   Checkpoint
   |type=    RBID
   |clé=     PMC:4651153
   |texte=   Breast Cancer: State of the Art and New Findings
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i   -Sk "pubmed:26640286" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Breast Cancer: State of the Art and New Findings

Breast Cancer: State of the Art and New Findings

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki